Acute urticaria as a side effect of the Mirena® (levonorgestrel-releasing intrauterine system): a case report
© Chen et al.; licensee BioMed Central Ltd. 2014
Received: 25 August 2013
Accepted: 21 March 2014
Published: 3 April 2014
The levonorgestrel intrauterine system, Mirena®, is widely used for contraception and the treatment of idiopathic menorrhagia. Here, we reported one case of acute urticaria following Mirena® implantation to increase the awareness of possible adverse side effects associated with Mirena®.
The case presented is a 27-year-old Chinese woman who received Mirena® implantation for her adenomyosis and menorrhagia. The operation was successful and the patient did not experience any discomfort during the operation. However, she developed acute urticaria on her entire body accompanied with pruritic, slight left lower quadrant pain, and slight dizziness two hours after the operation. The patient was recommended to have the Mirena® removed immediately, and she took 10 mg oral methylprednisolone and 5 mg desloratadine tablet daily for five days. Her urticaria resolved and did not recur.
The patient’s acute urticaria seems to have been associated with the Mirena® levonorgestrel intrauterine system implantation, since she had no history of allergic reactions to materials used during the operation such as plastic, metal, alcohol, medications, and povidone-iodine.
KeywordsMirena® Allergic reactions
The levonorgestrel intrauterine system (LNG-IUS), Mirena®, is a commonly used contraceptive device in clinical practice. In addition to providing effective contraception, Mirena® is also frequently used to treat idiopathic menorrhagia and protect the uterus from endometrial hyperplasia in estrogen replacement therapy . Adverse side effects associated with Mirena® implantation include acne, menstrual disorder, pelvic pain, and ovarian cysts. Most of these symptoms can resolve spontaneously within several months [1–3]. Adverse skin reactions to Mirena® are rare. Karri et al. reported one case of severe seborrhoeic dermatitis, which is thought to associate with the levonorgestrel in Mirena® . Here, we reported one case of acute urticaria following Mirena® implantation. The patient was advised to have the Mirena® removed immediately and took 10 mg oral methylprednisolone and 5 mg desloratadine tablet daily for five days. Her urticaria then resolved and did not recur.
A 27-year-old Chinese woman gravida 1 para 1 was treated with Mirena® implantation for adenomyosis and menorrhagia in our hospital in September 2012. The patient was in good general health and had regular menstrual cycles. She had a caesarean section to deliver a baby boy in 2003. Six months after the delivery, she received a triangular-shaped metal intrauterine device (IUD) insertion for contraception. The IUD was then removed two months later due to unbearable vaginal spotting. The patient had a history of moderate alcohol consumption but no history of allergic reactions to plastic, metal, alcohol, medications, and povidone-iodine. Her routine gynecological examination before the operation appeared normal.
The diagnosis from a dermatologist was acute urticaria possibly caused by allergic reactions. The patient was advised to have the Mirena® removed immediately. After the Mirena® was removed, her pruritic was slightly relieved. The patient then took 10 mg oral methylprednisolone and 5 mg desloratadine tablet daily for five days. The patient came back to follow-up visit three days after the operation. Her abdominal pain and pruritic resolved completely, her skin condition also improved significantly (Figure 1C and D). The medication was discontinued five days after the operation. Her urticaria subsided and did not recur.
The most commonly recognized side effects associated with Mirena® are vaginal bleeding or spotting, amenorrhea, and benign ovarian cysts [1–3]. Although adverse skin reactions to Mirena® are rarely seen, a few cases of skin condition have been reported to associate with Mirena® implantation. Karri et al. presented a case of severe seborrhoeic dermatitis . Levonorgestrel is the hormonal component of the Mirena® LNG-IUS. The patient’s seborrhoeic dermatitis is thought to be caused by the levonorgestrel released from the Mirena®, because her skin condition was improved quickly after the removal of the Mirena®. Pereira et al. reported a case of autoimmune progesterone dermatitis. In their report, the patient developed itchy skin rash 24 hours after a Mirena® IUS insertion. Her symptoms were initially alleviated by local steroid and oral antihistamines, but resolved eventually by the removal of the Mirena® IUS .
In this report, this was the first case of acute urticaria possibly associated with Mirena® implantation we encountered in our hospital. This patient developed a rash eruption on her entire body 2 hours after the implantation. The lesions carry the typical characteristics of urticaria, such as intensive pruritus and becoming blanched completely with pressure. To determine the possible association between the lesions and the Mirena® implantation, we carefully examined the patient’s condition and medical history. The patient had no food intake before, during, and after the operation, eliminating food related allergic reactions. She was not on any regular medication and had no new medicines before the operation. Thus, drug allergies might be excluded. In addition, she had no history of allergic reactions to any medication or the material used during the operation including plastic, metal, alcohol, and povidone-iodine. The patient had no recent or chronic infections or other medical conditions. The only medical procedure she was exposed to was the Mirena® implantation. Based on these facts, we concluded that her urticarial condition was most likely due to the Mirena® implantation. Similar to the reports from Karri et al. and Pereira et al., the acute urticaria in this case might also be associated with the levonorgestrel released from the Mirena® LNG-IUS.
Although the rash is likely associated with Mirena® implantation, limitations regarding the diagnosis should not be ignored. Our diagnosis of Mirena® -induced acute urticaria is mainly based on the fact that the rash appeared 2 hours after the implantation and the patient did not have previous allergic reactions to the materials used during the operation. However, since we did not examine the serum levels of immunoglobulins indicating possible allergic reactions to the materials used during the operation, such as plastic, metal, alcohol, and povidone-iodine, the possibility that these things might contribute to the development of acute urticaria in this patient cannot be excluded completely. In addition, it has been known that emotional stress can induce acute urticaria as well. According to the patient’s medical history, in 2003, she had caesarean section and triangular-shaped metal IUD insertion for contraception, which have a similar operating procedure as Mirena® LNG-IUS implantation. Although the patient was not recorded to exhibit any abnormal reactions to the two previous operations, she might experience unusual anxiety and fear during the Mirena® implantation. Thus, we cannot completely rule out the possibility that the acute urticaria in this case might relate to the operation procedure but not directly associate with the Mirena® LNG-IUS device.
The levonorgestrel released from Mirena® is at a higher concentration in the uterus than that in the systemic circulation. Thus, the side effects of Mirena® are usually local and mild. We reported this case of acute urticaria possibly associated with Mirena® implantation to raise the awareness of the side effects of Mirena® and emphasize the prompt treatment for the adverse reactions.
We reported one case of acute urticaria possibly associated with Mirena® implantation. The patient’s adverse skin reaction might relate to the levonorgestrel released from the Mirena® LNG-IUS. Her symptoms were improved by oral steroid and antihistamines and removal of the Mirena®, and did not recur after the medication was discontinued.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Varma R, Sinha D, Gupta JK: Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol. 2006, 125: 9-28. 10.1016/j.ejogrb.2005.10.029.PubMedView ArticleGoogle Scholar
- Dubuissona JB, Mugnierb E, the Mirena® Study Groupa: Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years. Contraception. 2002, 66: 121-128. 10.1016/S0010-7824(02)00329-3.View ArticleGoogle Scholar
- Rauramo I, Elo I, Istre O: Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol. 2004, 104: 1314-1321. 10.1097/01.AOG.0000143824.16435.91.PubMedView ArticleGoogle Scholar
- Karri K, Mowbray D, Adams S, Rendall JRS: Severe seborrhoeic dermatitis: Side-effect of the Mirena intra-uterine system. Eur J Contracept Reprod Health Care. 2006, 11: 53-54.PubMedView ArticleGoogle Scholar
- Pereira A, Coker A: Hypersensitivity to mirena-a rare complication. J Obstet Gynaecol. 2003, 23: 81-92.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.